Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
The financial performance from 2019 to 2023 is characterized by extreme volatility in cash generation, exhibiting a sharp ascent followed by a significant contraction. The trajectory reflects a transition from initial cash consumption to an extraordinary peak in liquidity, returning to a negative cash flow position by the end of the period.
- Operational Cash Flow Dynamics
- Net cash provided by operating activities transitioned from a deficit of 459 million USD in 2019 to a peak of 13.62 billion USD in 2021. This represents a rapid escalation in operational efficiency or revenue realization. However, this trend reversed sharply starting in 2022, culminating in a deficit of 3.118 billion USD by December 31, 2023.
- Free Cash Flow to the Firm (FCFF) Trends
- FCFF mirrors the operational cash flow pattern closely. After a negative start of 485 million USD in 2019, FCFF surged to 1.966 billion USD in 2020 and reached a maximum of 13.223 billion USD in 2021. A precipitous decline followed, with FCFF dropping to 3.826 billion USD in 2022 and falling to a negative 3.794 billion USD in 2023.
- Correlation Between Operating Cash and FCFF
- A tight correlation is observed between net operating cash and FCFF throughout the five-year period. The narrow variance between these two metrics suggests that capital expenditures remained relatively stable and modest compared to the massive swings in operating cash flow, indicating that the primary driver of FCFF volatility was operational performance rather than aggressive capital investment.
- Analysis of the 2023 Reversal
- The shift to a negative FCFF of 3.794 billion USD in 2023 marks a complete reversal of the growth seen between 2020 and 2022. This indicates a return to a cash-burning phase, where outflows for operations and investments once again exceed the cash generated from core business activities.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2 2023 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= 39 × 21.00% = 8
An analysis of the financial outflows related to interest expenses reveals a consistent and accelerating upward trajectory from 2019 through 2023.
- Cash Paid for Interest, Net of Tax
- A steady increase in net interest payments is observed, rising from US$ 6 million in 2019 to US$ 31 million by the end of 2023. The growth was relatively moderate between 2019 and 2020, but the pace of increase intensified significantly starting in 2021, with the annual expenditure more than doubling between 2021 and 2023.
- Effective Income Tax Rate (EITR) Volatility
- The effective income tax rate exhibited notable fluctuations during the period. After standing at 21.00% in 2020, the rate declined sharply to 8.10% in 2021. A partial recovery followed in 2022 with a rate of 12.70%, before returning to the 21.00% level in 2023.
- Correlation Analysis
- The increase in cash paid for interest, net of tax, persisted despite the volatility in the effective income tax rate. Specifically, the period of the lowest tax rates (2021-2022) coincided with a rapid escalation in net interest payments. Because a lower tax rate reduces the tax shield on interest expenses, the net cash outflow increases; however, the magnitude of the rise in payments suggests that the underlying gross interest obligations grew substantially, outweighing the impact of tax rate fluctuations.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Enterprise Value to FCFF Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 11,320) |
| Free cash flow to the firm (FCFF) | (3,794) |
| Valuation Ratio | |
| EV/FCFF | — |
| Benchmarks | |
| EV/FCFF, Competitors1 | |
| AbbVie Inc. | 29.55 |
| Amgen Inc. | 28.72 |
| Bristol-Myers Squibb Co. | 11.48 |
| Danaher Corp. | 32.13 |
| Eli Lilly & Co. | 144.44 |
| Gilead Sciences Inc. | 22.56 |
| Johnson & Johnson | 32.50 |
| Merck & Co. Inc. | 30.09 |
| Pfizer Inc. | 19.96 |
| Regeneron Pharmaceuticals Inc. | 23.78 |
| Thermo Fisher Scientific Inc. | 37.17 |
| Vertex Pharmaceuticals Inc. | 41.41 |
| EV/FCFF, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 40.42 |
| EV/FCFF, Industry | |
| Health Care | 34.89 |
Based on: 10-K (reporting date: 2023-12-31).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 28,826) | 44,973) | 51,004) | 57,415) | 8,579) | |
| Free cash flow to the firm (FCFF)2 | (3,794) | 3,826) | 13,223) | 1,966) | (485) | |
| Valuation Ratio | ||||||
| EV/FCFF3 | — | 11.76 | 3.86 | 29.20 | — | |
| Benchmarks | ||||||
| EV/FCFF, Competitors4 | ||||||
| AbbVie Inc. | 14.89 | 12.15 | 13.18 | — | — | |
| Amgen Inc. | 22.22 | 16.01 | 15.82 | — | — | |
| Bristol-Myers Squibb Co. | 9.14 | 13.87 | 10.52 | — | — | |
| Danaher Corp. | 36.34 | 25.74 | 28.25 | — | — | |
| Eli Lilly & Co. | 655.43 | 59.17 | 38.39 | — | — | |
| Gilead Sciences Inc. | 13.41 | 13.58 | 8.42 | — | — | |
| Johnson & Johnson | 19.30 | 23.80 | 21.25 | — | — | |
| Merck & Co. Inc. | 37.84 | 19.09 | 23.27 | — | — | |
| Pfizer Inc. | 32.24 | 9.15 | 8.40 | — | — | |
| Regeneron Pharmaceuticals Inc. | 25.33 | 23.31 | 9.81 | — | — | |
| Thermo Fisher Scientific Inc. | 28.85 | 31.61 | 33.14 | — | — | |
| Vertex Pharmaceuticals Inc. | 29.45 | 16.68 | 22.47 | — | — | |
| EV/FCFF, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 27.29 | 18.08 | 16.12 | — | — | |
| EV/FCFF, Industry | ||||||
| Health Care | 25.98 | 18.66 | 17.80 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
3 2023 Calculation
EV/FCFF = EV ÷ FCFF
= 28,826 ÷ -3,794 = —
4 Click competitor name to see calculations.
The financial trajectory from 2019 to 2023 is characterized by extreme volatility in both market valuation and cash flow generation. A period of rapid expansion in enterprise value was mirrored by a surge in free cash flow to the firm, followed by a consistent contraction in valuation and a return to negative cash flow generation by the end of the period.
- Enterprise Value (EV) Trajectory
- Enterprise value experienced a substantial increase between 2019 and 2020, rising from 8,579 million to a peak of 57,415 million. Subsequently, a consistent downward trend was observed over the following three years, with the value declining to 28,826 million by December 31, 2023, representing a significant contraction from the 2020 peak.
- Free Cash Flow to the Firm (FCFF) Performance
- Cash flow generation demonstrated high variance throughout the period. After recording a deficit of 485 million in 2019, FCFF shifted to a positive position in 2020 and reached a peak of 13,223 million in 2021. This growth reversed sharply in 2022, falling to 3,826 million, and ultimately returned to a negative position of 3,794 million in 2023.
- EV/FCFF Ratio Interpretation
- The valuation multiple shifted dramatically in response to the fluctuations in cash flow. In 2020, the ratio stood at 29.20, reflecting a high valuation relative to available cash flows. This multiple compressed to 3.86 in 2021, driven by the peak in FCFF. By 2022, the ratio expanded to 11.76 as cash flow declined more rapidly than the enterprise value. For 2019 and 2023, the ratio was non-calculable due to negative FCFF, indicating periods where the firm was consuming rather than generating free cash flow.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?